STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews: A Journal of Pharmacology Review Article

Pharmacogenomics in Anesthesia: Case Studies and Clinical Applications for Personalized Care

  1. Tehseen Irshad St.Soldier Group of Institutions, Jalandhar
  2. Bilal GMC Baramullah, Jalandhar
  3. Sowby Jan St.Soldier Group of Institutions, Jalandhar

Abstract

Pharmacogenomics, the study of how genetic variability influences individual responses to medications, is transforming anesthetic practice by enabling personalized care. This case study collection explores the integration of pharmacogenomic insights into anesthesia management, highlighting its impact on safety, efficacy, and patient outcomes. Adverse reactions to anesthetics often arise from genetic polymorphisms that alter drug metabolism or sensitivity. For instance, patients with RYR1 mutations are susceptible to malignant hyperthermia (MH) when exposed to volatile anesthetics like isoflurane. Case studies demonstrate how rapid intervention with dantrolene can mitigate life-threatening crises. Similarly, genetic variations in GABRG2 and CYP2D6 influence recovery times and opioid metabolism, requiring tailored anesthetic regimens. Detailed analyses of personalized approaches further underscore the value of pharmacogenomics. Adjusted propofol dosing based on UGT1A9 polymorphisms prevented prolonged sedation in a high-risk patient, while selecting alternative opioids, like hydromorphone, for a CYP2D6 poor metabolizer enhanced pain control without side effects. The use of rocuronium instead of succinylcholine for a patient with BCHE gene variants averted prolonged paralysis, showcasing precision in neuromuscular blockade management. Beyond drug selection, pharmacogenomic data guided antiemetic therapy, reducing postoperative nausea and vomiting (PONV) in patients with HTR3A polymorphisms. By tailoring interventions to individual genetic profiles, anesthesiologists ensured improved patient comfort and satisfaction. This collection also includes appendices on genetic testing workflows, dosing guidelines, and ethical considerations, providing a comprehensive framework for integrating pharmacogenomics into clinical practice.

Keywords

References (14)

  1. Weinshilboum RM, Wang L. Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Annual Review of Genomics and Human Genetics. 2006;7(1):223-245. doi:10.1146/annurev.genom.6.080604.162315
  2. Meyer UA. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nature Reviews Genetics. 2004;5(9):669-676. doi:10.1038/nrg1428
  3. Flockhart DA. Cytochrome P450 Drug Interaction Table. Clin Pharmacol Ther. 2007;81(1):45–9.
  4. Evans WE, Relling MV. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science. 1999;286(5439):487-491. doi:10.1126/science.286.5439.487
  5. Voora D, McLeod HL, Eby C, Gage BF. The Pharmacogenetics of Coumarin Therapy. Pharmacogenomics. 2005;6(5):503-513. doi:10.2217/14622416.6.5.503
  6. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annual Review of Pharmacology and Toxicology. 2015;55(1):89-106. doi:10.1146/annurev-pharmtox-010814-124835
  7. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: Relevance in medical practice. Cleveland Clinic Journal of Medicine. 2011;78(4):243-257. doi:10.3949/ccjm.78a.10145
  8. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions. JAMA. 2001;286(18):2270. doi:10.1001/jama.286.18.2270
  9. McLeod HL, Evans WE. Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy. Annual Review of Pharmacology and Toxicology. 2001;41(1):101-121. doi:10.1146/annurev.pharmtox.41.1.101
  10. Roden DM, George Jr AL. The genetic basis of variability in drug responses. Nature Reviews Drug Discovery. 2002;1(1):37-44. doi:10.1038/nrd705
  11. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Translational Research. 2009;154(6):277-287. doi:10.1016/j.trsl.2009.09.005
  12. Ahmad M, Abu Tabar N, Othman EH, Abdelrahim Z. Shared Decision-Making Measures: A Systematic Review. Quality Management in Health Care. 2020;29(2):54-66. doi:10.1097/qmh.0000000000000250
  13. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. New England Journal of Medicine. 2009;360(8):753-764. doi:10.1056/nejmoa0809329
  14. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Derijks HJ, Brouwers JR, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73.
Support